1. Metabolic Enzyme/Protease
  2. Acyltransferase
  3. Avasimibe

Avasimibe  (Synonyms: CI-1011; PD-148515)

Cat. No.: HY-13215 Purity: 99.77%
Handling Instructions Technical Support

Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor with IC50s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively. Avasimibe can be used for the research of prostate cancer.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No. : 166518-60-1

사이즈 가격 재고 수량
무료 샘플 (0.1 - 0.2 mg)   지금 신청하기  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
해외재고보유
Solution
10 mM * 1 mL in DMSO 해외재고보유
Solid
5 mg 해외재고보유
10 mg 해외재고보유
25 mg 해외재고보유
50 mg 해외재고보유
100 mg 해외재고보유
200 mg 해외재고보유
500 mg   견적 받기  
1 g   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 17 publication(s) in Google Scholar

Other Forms of Avasimibe:

Top Publications Citing Use of Products

    Avasimibe purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Dec 19.  [Abstract]

    Avasimibe (20 μM; 24 h). Western blot analysis of the expression levels of ACAT1 and IDH2-K272la in CMECs treated with the ACAT1 inhibitor Avasimibe under NOD and HOD stimulation.

    Avasimibe purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Dec 19.  [Abstract]

    Avasimibe (20 μM; 24 h). Coimmunoprecipitation experiment assessing the binding capacity of Cav1 with IDH2 and eNOS in CMECs treated with the ACAT1 inhibitor Avasimibe under NOD and HOD stimulation.

    Avasimibe purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Dec 19.  [Abstract]

    Avasimibe (20 μM; 24 h). Evaluation of tube formation, EdU proliferation, and NO production capabilities of CMECs treated with the ACAT1 inhibitor Avasimibe under HOD stimulation.

    Avasimibe purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Oct;130:110508.  [Abstract]

    Avasimibe (7.5 μM; 0-72 h). Inhibitory effects of Avasimibe on cell viability of T98 G and LN229 at different times.

    Avasimibe purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Oct;130:110508.  [Abstract]

    qRT-PCR data showing the expression of linc00339 in T98 G or LN229 cells treated with linc00339 plasmid, Avasimibe (7.5 μM for 48 h) alone or in combination with linc00339 plasmids.

    Avasimibe purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Oct;130:110508.  [Abstract]

    Colony formation assays showing the proliferation capacity of T98 G or LN229 cells treated with linc00339 plasmid, Avasimibe (7.5 μM for 48 h) alone or in combination with linc00339 plasmids.

    Avasimibe purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Oct;130:110508.  [Abstract]

    Avasimibe (7.5 μM for 48 h). LN229 cells treated with Avasimibe or combined with linc00339 plasmid were subcutaneously injected into the nude mice. Tumour formation in nude mice.

    Avasimibe purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Oct;130:110508.  [Abstract]

    Transwell assays showing the invasion capacity of T98 G or LN229 cells treated with linc00339 plasmid, Avasimibe (7.5 μM for 48 h) alone or in combination with linc00339 plasmids.

    View All Acyltransferase Isoform Specific Products:

    • Biological Activity

    • 순도&문서

    • References

    • 고객리뷰

    제품 설명

    Avasimibe (CI-1011; PD-148515) is an orally active acyl coenzyme A-cholesterol acyltransferase (ACAT; also called SOAT)) inhibitor with IC50s of 24 and 9.2 µM for ACAT1 and ACAT2, respectively[1]. Avasimibe can be used for the research of prostate cancer[2].

    IC50 & Target[1]

    ACAT1

    24 μM (IC50)

    ACAT2

    9.2 μM (IC50)

    Cellular Effect
    Cell Line Type Value Description References
    Caco-2 CC50
    13.71 μM
    Compound: AVASIMIBE
    Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay
    Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay
    10.21203/rs.3.rs-23951/v1
    Caco-2 IC50
    3.93 μM
    Compound: AVASIMIBE
    Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging
    Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging
    10.21203/rs.3.rs-23951/v1
    HepG2 IC50
    479 nM
    Compound: avasimibe
    Inhibition of ACAT in human HepG2 cells
    Inhibition of ACAT in human HepG2 cells
    [PMID: 19167888]
    THP-1 IC50
    1.5 μM
    Compound: avasimibe
    Inhibition of ACAT-mediated esterified cholesterol accumulation in human THP1 cells exposed to acetyl-LDL during differentiation assessed as effect on foam cell formation
    Inhibition of ACAT-mediated esterified cholesterol accumulation in human THP1 cells exposed to acetyl-LDL during differentiation assessed as effect on foam cell formation
    [PMID: 18620381]
    In Vitro

    Avasimibe (0, 0.25, 5, 10, 20, 40 and 80 μM; for 1, 2, and 3 days) reduces proliferation in the prostate cancer (PCa) cells[2].
    Avasimibe (10 and 20 μM; 48 h) reduces the expression of β-catenin, Vimentin, N-cadherin, Snail and MMP9, which are tightly associated with epithelial-mesenchymal transition (EMT)[2].
    Avasimibe (10 and 20 μM) trigger cell cycle arrest via the E2F-1 signalling pathway in prostate cancer. Avasimibe induces G1 phase cell cycle arrest of PCa cells[2].
    Avasimibe (10 and 20 μM) inhibits the metastasis of PCa cells[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Viability Assay[2]

    Cell Line: PCa cells (PC-3 and DU 145)
    Concentration: 0, 0.25, 5, 10, 20, 40 and 80 µM
    Incubation Time: 1, 2, and 3 days
    Result: Dose dependently inhibited PC-3 and DU 145 cell viability.

    Western Blot Analysis[2]

    Cell Line: PCa cells (PC-3 and DU 145)
    Concentration: 10 and 20 µM
    Incubation Time: 48 hours
    Result: Reduced protein levels of EMT-related proteins (β-catenin, Vimentin, N-cadherin, Snail, MMP9 and E-cadherin).

    Cell Cycle Analysis[2]

    Cell Line: PCa cells (PC-3 and DU 145)
    Concentration: 10 and 20 µM
    Incubation Time: 48 hours
    Result: Induced G1 phase cycle arrest and altered the G1 phase-related protein levels in PCa cells.
    In Vivo

    Avasimibe (30 mg/kg, intraperitoneally injected on alternate days for 7 weeks) suppresses PCa cell growth and metastasis in vivo. Avasimibe has good biocompatibility and low toxicity[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: SPF male mice (BALB/c-nude, 4 weeks old) bearing PCa cells[2]
    Dosage: 30 mg/kg
    Administration: Intraperitoneally injected for 7 weeks
    Result: Reduced tumour volume compared with that of the control group. Inhibited PCa growth and migration in vivo.
    분자량

    501.72

    화학식

    C29H43NO4S

    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(NS(=O)(OC1=C(C(C)C)C=CC=C1C(C)C)=O)CC2=C(C(C)C)C=C(C(C)C)C=C2C(C)C

    선적

    Room temperature in continental US; may vary elsewhere.

    보관
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    용액&용해도
    In Vitro: 

    DMSO : 100 mg/mL (199.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.9931 mL 9.9657 mL 19.9314 mL
    5 mM 0.3986 mL 1.9931 mL 3.9863 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • 몰농도 계산기

    • 농도 희석 계산기

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 7.5 mg/mL (14.95 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 7.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 7.5 mg/mL (14.95 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 7.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    순도&문서

    Purity: 99.85%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.9931 mL 9.9657 mL 19.9314 mL 49.8286 mL
    5 mM 0.3986 mL 1.9931 mL 3.9863 mL 9.9657 mL
    10 mM 0.1993 mL 0.9966 mL 1.9931 mL 4.9829 mL
    15 mM 0.1329 mL 0.6644 mL 1.3288 mL 3.3219 mL
    20 mM 0.0997 mL 0.4983 mL 0.9966 mL 2.4914 mL
    25 mM 0.0797 mL 0.3986 mL 0.7973 mL 1.9931 mL
    30 mM 0.0664 mL 0.3322 mL 0.6644 mL 1.6610 mL
    40 mM 0.0498 mL 0.2491 mL 0.4983 mL 1.2457 mL
    50 mM 0.0399 mL 0.1993 mL 0.3986 mL 0.9966 mL
    60 mM 0.0332 mL 0.1661 mL 0.3322 mL 0.8305 mL
    80 mM 0.0249 mL 0.1246 mL 0.2491 mL 0.6229 mL
    100 mM 0.0199 mL 0.0997 mL 0.1993 mL 0.4983 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    최근 본 상품:

    온라인 문의

    Your information is safe with us. * Required Fields.

    상품명

     

    Requested Quantity *

    고객명 *

     

    호칭

    메일주소 *

     

    전화번호 *

    Department

     

    회사명 *

    City

    Country or Region *

         

    비고

    대량구매 문의

    Inquiry Information

    상품명:
    Avasimibe
    Cat. No.:
    HY-13215
    수량:
    MCE Japan Authorized Agent: